E Fund Management Co., Ltd. 89bio, Inc. Transaction History

E Fund Management Co., Ltd.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$8.13 - $13.77 $20,593 - $34,879	-2,533 Reduced 10.4%	21,830 $254,000
Q4 2023 Feb 06, 2024	BUY	$6.66 - $16.03 $31,581 - $76,014	4,742 Added 24.17%	24,363 $272,000
Q3 2023 Nov 13, 2023	SELL	$15.06 - $19.41 $29,863 - $38,490	-1,983 Reduced 9.18%	19,621 $303,000
Q2 2023 Aug 11, 2023	BUY	$14.15 - $22.03 $49,015 - $76,311	3,464 Added 19.1%	21,604 $409,000
Q1 2023 May 11, 2023	BUY	$10.48 - $16.94 $190,107 - $307,291	18,140 New	18,140 $276,000

158

108M

73.6K

1.19M

Ticker ETNB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,484,500
Market Cap $415M
Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...

Get notified when there are updates to the investment portfolio of E Fund Management Co., Ltd., based on Form 13F filings with the SEC.

Stay updated on E Fund Management Co., Ltd. with notifications on news.